Platelets disrupt vasculogenic mimicry by cancer cells.
Animals
Apoptosis
/ drug effects
Aspirin
/ therapeutic use
Blood Platelets
/ pathology
Breast Neoplasms
/ pathology
Cell Line, Tumor
Female
Male
Melanoma
/ pathology
Mice
Mice, Inbred BALB C
Neoplasm Metastasis
Neoplasm Transplantation
Neoplasms
/ blood supply
Neovascularization, Pathologic
/ pathology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 04 2020
03 04 2020
Historique:
received:
04
06
2018
accepted:
13
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
26
11
2020
Statut:
epublish
Résumé
Tumour vasculature supports the growth and progression of solid cancers with both angiogenesis (endothelial cell proliferation) and vasculogenic mimicry (VM, the formation of vascular structures by cancer cells themselves) predictors of poor patient outcomes. Increased circulating platelet counts also predict poor outcome for cancer patients but the influence of platelets on tumour vasculature is incompletely understood. Herein, we show with in vitro assays that platelets did not influence angiogenesis but did actively inhibit VM formation by cancer cell lines. Both platelet sized beads and the releasates from platelets were partially effective at inhibiting VM formation suggesting that direct contact maximises the effect. Platelets also promoted cancer cell invasion in vitro. B16F10 melanomas in Bcl-x
Identifiants
pubmed: 32246008
doi: 10.1038/s41598-020-62648-x
pii: 10.1038/s41598-020-62648-x
pmc: PMC7125143
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5869Références
Levin, J. & Conley, C. L. Thrombocytosis Associated with Malignant Disease. Arch. Intern. Med. 114, 497–500 (1964).
doi: 10.1001/archinte.1964.03860100079008
Pedersen, L. M. & Milman, N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur. Respir. J. 9, 1826–1830 (1996).
doi: 10.1183/09031936.96.09091826
Stravodimou, A. & Voutsadakis, I. A. Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer. Int. J. Breast Cancer 2013, 289563, https://doi.org/10.1155/2013/289563 (2013).
doi: 10.1155/2013/289563
pubmed: 3707237
pmcid: 3707237
Hyslop, S. R. & Josefsson, E. C. Undercover Agents: Targeting Tumours with Modified Platelets. Trends Cancer 3, 235–246, https://doi.org/10.1016/j.trecan.2017.01.006 (2017).
doi: 10.1016/j.trecan.2017.01.006
Felding-Habermann, B., Habermann, R., Saldivar, E. & Ruggeri, Z. M. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J. Biol. Chem. 271, 5892–5900 (1996).
doi: 10.1074/jbc.271.10.5892
Nieswandt, B., Hafner, M., Echtenacher, B. & Mannel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295–1300 (1999).
Rolli, M., Fransvea, E., Pilch, J., Saven, A. & Felding-Habermann, B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 9482–9487, https://doi.org/10.1073/pnas.1633689100 (2003).
doi: 10.1073/pnas.1633689100
Deryugina, E. I. & Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9–34, https://doi.org/10.1007/s10555-006-7886-9 (2006).
doi: 10.1007/s10555-006-7886-9
Pinedo, H. M., Verheul, H. M., D’Amato, R. J. & Folkman, J. Involvement of platelets in tumour angiogenesis? Lancet 352, 1775–1777 (1998).
doi: 10.1016/S0140-6736(98)05095-8
Mohle, R., Green, D., Moore, M. A., Nachman, R. L. & Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl Acad. Sci. USA 94, 663–668 (1997).
doi: 10.1073/pnas.94.2.663
Ay, C., Pabinger, I. & Cohen, A. T. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb. Haemost. 117, 219–230, https://doi.org/10.1160/TH16-08-0615 (2017).
doi: 10.1160/TH16-08-0615
De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474, https://doi.org/10.1038/nrc.2017.51 (2017).
doi: 10.1038/nrc.2017.51
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186, https://doi.org/10.1056/NEJM197111182852108 (1971).
doi: 10.1056/NEJM197111182852108
Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123–134, https://doi.org/10.1038/nrc3004 (2011).
doi: 10.1038/nrc3004
pubmed: 6894505
pmcid: 6894505
Chatterjee, M. et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood 117, 3907–3911, https://doi.org/10.1182/blood-2010-12-327007 (2011).
doi: 10.1182/blood-2010-12-327007
Ho-Tin-Noe, B., Goerge, T., Cifuni, S. M., Duerschmied, D. & Wagner, D. D. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res. 68, 6851–6858, https://doi.org/10.1158/0008-5472.CAN-08-0718 (2008).
doi: 10.1158/0008-5472.CAN-08-0718
pubmed: 2547489
pmcid: 2547489
Jiang, L. et al. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. Br. J. Cancer 117, 695–703, https://doi.org/10.1038/bjc.2017.214 (2017).
doi: 10.1038/bjc.2017.214
pubmed: 5572171
pmcid: 5572171
Yan, M., Lesyk, G., Radziwon-Balicka, A. & Jurasz, P. Pharmacological regulation of platelet factors that influence tumor angiogenesis. Semin. Oncol. 41, 370–377, https://doi.org/10.1053/j.seminoncol.2014.04.007 (2014).
doi: 10.1053/j.seminoncol.2014.04.007
Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. N. Biol. 231, 232–235 (1971).
doi: 10.1038/newbio231232a0
Chia, W. K., Ali, R. & Toh, H. C. Aspirin as adjuvant therapy for colorectal cancer–reinterpreting paradigms. Nat. Rev. Clin. Oncol. 9, 561–570, https://doi.org/10.1038/nrclinonc.2012.137 (2012).
doi: 10.1038/nrclinonc.2012.137
Bibbins-Domingo, K. & Force, U. S. P. S. T. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 164, 836–845, https://doi.org/10.7326/M16-0577 (2016).
doi: 10.7326/M16-0577
Blanco, F. J., Guitian, R., Moreno, J., de Toro, F. J. & Galdo, F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J. Rheumatol. 26, 1366–1373 (1999).
Voora, D. et al. Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. EBioMedicine 11, 157–164, https://doi.org/10.1016/j.ebiom.2016.08.021 (2016).
doi: 10.1016/j.ebiom.2016.08.021
pubmed: 5049978
pmcid: 5049978
Alfonso, L., Ai, G., Spitale, R. C. & Bhat, G. J. Molecular targets of aspirin and cancer prevention. Br. J. Cancer 111, 61–67, https://doi.org/10.1038/bjc.2014.271 (2014).
doi: 10.1038/bjc.2014.271
pubmed: 4090734
pmcid: 4090734
Hanif, R. et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52, 237–245 (1996).
doi: 10.1016/0006-2952(96)00181-5
Dovizio, M., Bruno, A., Tacconelli, S. & Patrignani, P. Mode of action of aspirin as a chemopreventive agent. Recent. Results Cancer Res. 191, 39–65, https://doi.org/10.1007/978-3-642-30331-9_3 (2013).
doi: 10.1007/978-3-642-30331-9_3
Etulain, J., Fondevila, C., Negrotto, S. & Schattner, M. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br. J. Pharmacol. 170, 255–265, https://doi.org/10.1111/bph.12250 (2013).
doi: 10.1111/bph.12250
pubmed: 3834751
pmcid: 3834751
Abdelrahim, M. & Safe, S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol. 68, 317–329, https://doi.org/10.1124/mol.105.011825 (2005).
doi: 10.1124/mol.105.011825
Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411–421, https://doi.org/10.1038/nrc1092 (2003).
doi: 10.1038/nrc1092
Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739–752, https://doi.org/10.1016/s0002-9440(10)65173-5 (1999).
doi: 10.1016/s0002-9440(10)65173-5
pubmed: 1866899
pmcid: 1866899
Yang, J. P. et al. Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis 19, 191–200, https://doi.org/10.1007/s10456-016-9500-2 (2016).
doi: 10.1007/s10456-016-9500-2
Demou, Z. N. & Hendrix, M. J. Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J. Cell Biochem. 105, 562–573, https://doi.org/10.1002/jcb.21855 (2008).
doi: 10.1002/jcb.21855
pubmed: 2654186
pmcid: 2654186
Dunleavey, J. M. et al. Vascular channels formed by subpopulations of PECAM1+ melanoma cells. Nat. Commun. 5, 5200, https://doi.org/10.1038/ncomms6200 (2014).
doi: 10.1038/ncomms6200
pubmed: 4261234
pmcid: 4261234
Hillen, F. et al. A transgenic Tie2-GFP athymic mouse model; a tool for vascular biology in xenograft tumors. Biochem. Biophys. Res. Commun. 368, 364–367, https://doi.org/10.1016/j.bbrc.2008.01.080 (2008).
doi: 10.1016/j.bbrc.2008.01.080
Ruf, W. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63, 5381–5389 (2003).
Shirakawa, K. et al. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res. 5, 136–139, https://doi.org/10.1186/bcr585 (2003).
doi: 10.1186/bcr585
pubmed: 165001
pmcid: 165001
de Souza Junior, D. A., Borges, A. C., Santana, A. C., Oliver, C. & Jamur, M. C. Mast Cell Proteases 6 and 7 Stimulate Angiogenesis by Inducing Endothelial Cells to Release Angiogenic Factors. PLoS One 10, e0144081, https://doi.org/10.1371/journal.pone.0144081 (2015).
doi: 10.1371/journal.pone.0144081
Pipili-Synetos, E., Papadimitriou, E. & Maragoudakis, M. E. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br. J. Pharmacol. 125, 1252–1257, https://doi.org/10.1038/sj.bjp.0702191 (1998).
doi: 10.1038/sj.bjp.0702191
pubmed: 1565699
pmcid: 1565699
Banks, R. E. et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 77, 956–964 (1998).
doi: 10.1038/bjc.1998.158
Zucchella, M. et al. Human tumor cells cultured “in vitro” activate platelet function by producing ADP or thrombin. Haematologica 74, 541–545 (1989).
Mason, K. D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173–1186, https://doi.org/10.1016/j.cell.2007.01.037 (2007).
doi: 10.1016/j.cell.2007.01.037
Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. Chapter 20, Unit 20 21, https://doi.org/10.1002/0471142735.im2001s39 (2001).
doi: 10.1002/0471142735.im2001s39
Lucotti, S. et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J. Clin. Invest. 129, 1845–1862, https://doi.org/10.1172/JCI121985 (2019).
doi: 10.1172/JCI121985
pubmed: 6486338
pmcid: 6486338
Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524, https://doi.org/10.1038/nature03799 (2005).
doi: 10.1038/nature03799
pubmed: 1283098
pmcid: 1283098
Coupland, L. A., Chong, B. H. & Parish, C. R. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 72, 4662–4671, https://doi.org/10.1158/0008-5472.CAN-11-4010 (2012).
doi: 10.1158/0008-5472.CAN-11-4010
Voora, D. et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J. Am. Coll. Cardiol. 62, 1267–1276, https://doi.org/10.1016/j.jacc.2013.05.073 (2013).
doi: 10.1016/j.jacc.2013.05.073
pubmed: 3786046
pmcid: 3786046
Mardente, S. et al. From Human Megakaryocytes to Platelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation End Products Axis. Front. Immunol. 8, 1946, https://doi.org/10.3389/fimmu.2017.01946 (2017).
doi: 10.3389/fimmu.2017.01946
Floyd, C. N. et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. Br. J. Clin. Pharmacol. 78, 320–328, https://doi.org/10.1111/bcp.12335 (2014).
doi: 10.1111/bcp.12335
pubmed: 4137824
pmcid: 4137824
Kuznetsov, H. S. et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2, 1150–1165, https://doi.org/10.1158/2159-8290.CD-12-0216 (2012).
doi: 10.1158/2159-8290.CD-12-0216
pubmed: 3517696
pmcid: 3517696
Pang, J. H., Coupland, L. A., Freeman, C., Chong, B. H. & Parish, C. R. Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process. Clin. Exp. Metastasis 32, 495–505, https://doi.org/10.1007/s10585-015-9722-5 (2015).
doi: 10.1007/s10585-015-9722-5
Battinelli, E. M., Markens, B. A. & Italiano, J. E. Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118, 1359–1369, https://doi.org/10.1182/blood-2011-02-334524 (2011).
doi: 10.1182/blood-2011-02-334524
pubmed: 3152500
pmcid: 3152500
Delgado-Bellido, D., Serrano-Saenz, S., Fernandez-Cortes, M. & Oliver, F. J. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol. Cancer 16, 65, https://doi.org/10.1186/s12943-017-0631-x (2017).
doi: 10.1186/s12943-017-0631-x
pubmed: 5359927
pmcid: 5359927
Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590, https://doi.org/10.1016/j.ccr.2011.09.009 (2011).
doi: 10.1016/j.ccr.2011.09.009
pubmed: 3487108
pmcid: 3487108
Gasic, G. J., Gasic, T. B. & Stewart, C. C. Antimetastatic effects associated with platelet reduction. Proc. Natl Acad. Sci. USA 61, 46–52 (1968).
doi: 10.1073/pnas.61.1.46
Maity, G. et al. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab. Invest. 95, 702–717, https://doi.org/10.1038/labinvest.2015.49 (2015).
doi: 10.1038/labinvest.2015.49
Carlson, L. M. et al. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 34, 1081–1088, https://doi.org/10.1093/carcin/bgt009 (2013).
doi: 10.1093/carcin/bgt009
Guillem-Llobat, P. et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 7, 32462–32477, https://doi.org/10.18632/oncotarget.8655 (2016).
doi: 10.18632/oncotarget.8655
pubmed: 5078026
pmcid: 5078026
Lichtenberger, L. M. et al. Unlocking Aspirin’s Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer Prev. Res. 10, 142–152, https://doi.org/10.1158/1940-6207.CAPR-16-0241 (2017).
doi: 10.1158/1940-6207.CAPR-16-0241
Reuter, B. K., Zhang, X. J. & Miller, M. J. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2, 19 (2002).
doi: 10.1186/1471-2407-2-19
Marshall, S. F. et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J. Natl Cancer Inst. 97, 805–812, https://doi.org/10.1093/jnci/dji140 (2005).
doi: 10.1093/jnci/dji140
Shiao, J. et al. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients. Breast Cancer Res. Treat. 161, 463–471, https://doi.org/10.1007/s10549-016-4081-8 (2017).
doi: 10.1007/s10549-016-4081-8
Gill, J. K. et al. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am. J. Epidemiol. 166, 1150–1158, https://doi.org/10.1093/aje/kwm195 (2007).
doi: 10.1093/aje/kwm195
Lampugnani, M. G. et al. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J. Cell Biol. 118, 1511–1522 (1992).
doi: 10.1083/jcb.118.6.1511
Dejana, E. & Vestweber, D. The role of VE-cadherin in vascular morphogenesis and permeability control. Prog. Mol. Biol. Transl. Sci. 116, 119–144, https://doi.org/10.1016/B978-0-12-394311-8.00006-6 (2013).
doi: 10.1016/B978-0-12-394311-8.00006-6
Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018–8023, https://doi.org/10.1073/pnas.131209798 (2001).
doi: 10.1073/pnas.131209798
Lampugnani, M. G., Dejana, E. & Giampietro, C. Vascular Endothelial (VE)-Cadherin, Endothelial Adherens Junctions, and Vascular Disease. Cold Spring Harb Perspect Biol 10, https://doi.org/10.1101/cshperspect.a029322 (2018).
Delgado-Bellido, D. et al. VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression. Cell Death Differ. 26, 348–361, https://doi.org/10.1038/s41418-018-0125-4 (2019).
doi: 10.1038/s41418-018-0125-4
Miyamori, H. et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. J. Biol. Chem. 276, 28204–28211, https://doi.org/10.1074/jbc.M103083200 (2001).
doi: 10.1074/jbc.M103083200
Williams, T. M. et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279, 51630–51646, https://doi.org/10.1074/jbc.M409214200 (2004).
doi: 10.1074/jbc.M409214200
Sun, B. et al. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 249, 188–197, https://doi.org/10.1016/j.canlet.2006.08.016 (2007).
doi: 10.1016/j.canlet.2006.08.016
Yin, M. J., Yamamoto, Y. & Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396, 77–80, https://doi.org/10.1038/23948 (1998).
doi: 10.1038/23948
Shi, C. et al. Aspirin Inhibits IKK-beta-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. Cell Physiol. Biochem. 41, 1313–1324, https://doi.org/10.1159/000464434 (2017).
doi: 10.1159/000464434
Cezar-de-Mello, P. F., Nascimento-Silva, V., Villela, C. G. & Fierro, I. M. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 25, 122–129, https://doi.org/10.1038/sj.onc.1209002 (2006).
doi: 10.1038/sj.onc.1209002
Cazenave, J. P. et al. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol. Biol. 272, 13–28, https://doi.org/10.1385/1-59259-782-3:013 (2004).
doi: 10.1385/1-59259-782-3:013
Ebert, L. M. et al. A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis 19, 463–486, https://doi.org/10.1007/s10456-016-9520-y (2016).
doi: 10.1007/s10456-016-9520-y
pubmed: 5026727
pmcid: 5026727
Tan, L. Y. et al. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget 7, 46492–46508, https://doi.org/10.18632/oncotarget.10216 (2016).
doi: 10.18632/oncotarget.10216
pubmed: 5216812
pmcid: 5216812
Hennigan, R. F., Hawker, K. L. & Ozanne, B. W. Fos-transformation activates genes associated with invasion. Oncogene 9, 3591–3600 (1994).
Lebois, M. et al. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling. J. Thromb. Haemost. 14, 1882–1887, https://doi.org/10.1111/jth.13397 (2016).
doi: 10.1111/jth.13397
Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659–661, https://doi.org/10.1096/fj.07-9574LSF (2008).
doi: 10.1096/fj.07-9574LSF